Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2009

View Archived Issues

Fatostatin inhibits SREBP activation and reduces glucose levels and body weight in obese mice

DURATION-1 and -2 studies detail effects of once-weekly exenatide in type 2 diabetes

Listeria-based vaccine active against Her2/neu-expressing tumors in vivo

Double-blind trial shows potential of mycophenolate mofetil in pemphigus vulgaris

Randomized trial suggests preventive role of probucol in contrast-induced acute kidney injury

Sivelestat shows safety in clinical evaluation in IVIG-resistant Kawasaki disease

Dainippon Sumitomo and Sepracor complete tender offer

GDC-0941 to be evaluated in phase Ib trials in patients with advanced solid tumors

GSK and Prosensa sign collaboration for RNA-based therapeutics in DMD

Vaxin enters joint venture with AnC Bio for development of vaccines

Sosei assigns SD-281 drug discovery program to Biocopea

GSK withdraws centralized MAA for Zunrisa in postoperative nausea and vomiting

Phase II data show that QVA-149 is safe and improves bronchodilation in COPD

Ortho Clinical Diagnostics receives FDA approval for anti-HIV 1+2 test

BioSante completes its merger with Cell Genesys, will focus on LibiGel development

VEGFR, c-Raf and RET kinase inhibitors disclosed by MethylGene as oncolytics

Bristol-Myers Squibb claims 11beta-HSD1 inhibitors for diabetes and other conditions

Hepatitis C virus NS3 protease inhibitors described by Phenomix for HCV infection therapy

Merck & Co. claims angiotensin II receptor antagonists for the treatment of hypertension

Curemark enrolls first patients in phase III autism trial

Intercell starts European pivotal phase III trial for travelers' diarrhea vaccine

Lipsovir approved in Europe for recurrent herpes labialis

Otsuka acquires common shares of MethylGene

Oxigene to acquire VaxGen through stock-for-stock merger

Protalix presents topline results from phase III Uplyso trial

Sanofi Pasteur reports U.S. clinical trial results for its influenza A (H1N1) vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...